OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
The product will be manufactured at Lupin’s Nagpur facility in India
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
Collaboration enables Brenntag to serve pharma customers in EMEA with chromatography silica gels
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Phase 3 data expected in the second half of 2024
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Subscribe To Our Newsletter & Stay Updated
